The review is part of a government push to examine spending on messenger RNA-based vaccines, the technology that powered ...
The approval of AIM Vaccine's mRNA RSV vaccine for clinical trials in the U.S. is seen by analysts as further validation of the company's "Innovation + Expansion" capabilities, potentially providing ...
Shares of vaccine maker Moderna dropped more than 5% late Wednesday after reports that the Health and Human Services ...